المؤلفون: Brinkhuis, Francine, Julian, Elaine^{Aff2, IDs12961024011542_cor2}, van den Ham, Hendrika, Gianfrate, Fabrizio, Strammiello, Valentina, Berntgen, Michael, Pavlovic, Mira, Mol, Peter, Wasem, Jürgen, Van Dyck, Walter, Cardone, Antonella, Dierks, Christian, Schiel, Anja, Bernardini, Renato, Solà-Morales, Oriol, Ruof, Jörg^{Aff2, Aff15}, Goettsch, Wim^{Aff1, Aff16}

المصدر: Health Research Policy and Systems. 22(1)

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Brinkhuis, Francine

مصطلحات الفهرس: In this report, the trend in added benefit of novel oncology drugs was explored over time. All oncology drugs authorized by the EMA between 1995-2020 were considered. We focused on added benefit ratings of Health Technology Assessment (HTA) agencies of Europe and the US, as well as oncological frameworks and a French organization that publishes medical evaluations. Furthermore, we assessed the trend in drug revenues over time, as well as the association between added benefit and revenues., Master Thesis, Student Thesis

URL: https://studenttheses.uu.nl/handle/20.500.12932/44064

المؤلفون: Baij, Lambert^{Aff1, Aff2}, Astefanei, Alina, Hermans, Joen^{Aff1, Aff2}, Brinkhuis, Francine, Groenewegen, Heleen, Chassouant, Louise, Johansson, Sofia, Corthals, Garry, Tokarski, Caroline, Iedema, Piet, Keune, Katrien^{Aff1, Aff2}

المصدر: Heritage Science. 7(1)

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Brinkhuis, Francine

مصطلحات الفهرس: This report entails an analysis of the Cancer Drugs Fund, a policy that has been set up in England with the objective of improving access to innovative cancer drugs. The content and developments of the policy, the role of stakeholders, and criticism and successes of the policy were addressed in this thesis., Master Thesis, Student Thesis

URL: https://studenttheses.uu.nl/handle/20.500.12932/41483

المؤلفون: Brinkhuis, Francine

مصطلحات الفهرس: In this thesis, the feasibility of a pay-for-proof (PFP) pricing model was assessed. Innovative pricing and reimbursement models have the potential to ameliorate the impact of uncertainty, which is becoming increasingly important as a growing number of drugs are developed based on less comprehensive evidence. The PFP model links payment to a discount scheme based on decreasing uncertainty, thereby reflecting real-world value and facilitating patient access., Master Thesis, Student Thesis

URL: https://studenttheses.uu.nl/handle/20.500.12932/42999

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Baij, Lambert, Astefanei, Alina, Joen Hermans, Brinkhuis, Francine, Groenewegen, Heleen, Chassouant, Louise, Johansson, Sofia, Corthals, Garry, Tokarski, Caroline, Iedema, Piet, Keune, Katrien

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1328c2ff6034f3229595971fa80d9344

المؤلفون: Julian E; Secretariat of the European Access Academy (EAA), 4059 Basel, Switzerland., Solà-Morales O; HiTT Foundation, International University of Catalonia-UIC, 08015 Barcelona, Spain., Garcia MJ; F. Hoffmann-La Roche AG, 4070 Basel, Switzerland., Brinkhuis F; Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, 3584 CS Utrecht, The Netherlands.; National Health Care Institute, 1110 AH Diemen, The Netherlands., Pavlovic M; Medicines Development and Training (MDT) Services, 75020 Paris, France., Martín-Saborido C; Ministry of Health, Government of Spain, 28014 Madrid, Spain., Doeswijk R; European Hematology Association (EHA), 2514 AA The Hague, The Netherlands., Giuliani R; Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK., Willemsen A; National Health Care Institute, 1110 AH Diemen, The Netherlands., Goettsch W; Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, 3584 CS Utrecht, The Netherlands.; National Health Care Institute, 1110 AH Diemen, The Netherlands., Wörmann B; German Association of Hematology and Oncology (DGHO), 10178 Berlin, Germany.; Division of Hematology, Oncology and Tumor Immunology, Department of Medicine, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany., Dafni U; European Society for Medical Oncology (ESMO), 6900 Lugano, Switzerland.; National and Kapodistrian University of Athens, and Frontier Science Foundation Hellas, 15773 Athens, Greece., Bucher HC; Division of Clinical Epidemiology, University Hospital Basel and University of Basel, 4051 Basel, Switzerland., Pérez-Valderrama B; Oncology Department, University Hospital Virgen del Rocío, 41013 Sevilla, Spain., Bernardini R; Department of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Pharmacology, University of Catania, 95124 Catania, Italy., Gianfrate F; University of Ferrara, 44121 Ferrara, Italy., Uyl-de Groot CA; Erasmus School of Health Policy & Management, Institute for Medical Technology Assessment, Erasmus, University Rotterdam, 3062 Rotterdam, The Netherlands., Ruof J; Medical School of Hanover, 30625 Hanover, Germany.

المصدر: Journal of market access & health policy [J Mark Access Health Policy] 2024 Jun 22; Vol. 12 (3), pp. 128-143. Date of Electronic Publication: 2024 Jun 22 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101670174 Publication Model: eCollection Cited Medium: Print ISSN: 2001-6689 (Print) Linking ISSN: 20016689 NLM ISO Abbreviation: J Mark Access Health Policy Subsets: PubMed not MEDLINE